-
Mashup Score: 1ENVISION Trial of UGN-102 Shows Durable Responses in LG-IR-NMIBC - 7 hour(s) ago
Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6Sasanlimab Plus BCG Demonstrates EFS Benefit in NMIBC - 22 day(s) ago
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Sasanlimab + Bacillus Calmette-Guérin led to an improved event-free survival vs BCG alone in patients with non-muscle invasive bladder cancer. #NMIBC #BLCSM https://t.co/CEJ0H35L7N
-
-
Mashup Score: 1FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings - 1 month(s) ago
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer. #NMIBC #blcsm https://t.co/z8WxkBT3uY
-
-
Mashup Score: 1FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings - 2 month(s) ago
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer. #NMIBC #blcsm https://t.co/z8WxkBT3uY
-
-
Mashup Score: 1Behind the Phase 1 Study of TAR-210 in FGFR-Altered NMIBC - 2 month(s) ago
Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and intermediate-risk non–muscle invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and intermediate-risk non–muscle invasive bladder cancer. #NMIBC #blcsm https://t.co/HGZVGeDm2M
-
-
Mashup Score: 1
Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In an interview, @MarkTysonMD discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive #NMIBC with carcinoma in situ and data from the BOND-003 trial. #BLCSM | @MayoUrology https://t.co/zjibhdDiHv https://t.co/7Z518NmAK0
-
-
Mashup Score: 0
The phase 3 ENVISION study investigating UGN-102 previously met its primary end point of complete response rate.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
The investigational drug UGN-102 demonstrated a 12-month duration of response of 82.3% at 3 months after the first instillation in patients with low-grade intermediate-risk #NMIBC, according to findings from the phase 3 ENVISION trial. #BLCSM https://t.co/u7ZUbtG9kQ
-
-
Mashup Score: 3Early Data Shows Promise of TAR-210 in FGFR-Altered NMIBC - 9 month(s) ago
Antoni Vilaseca Cabo, MD, discusses phase 1 data presented on TAR-210 for the treatment of patients with FGFR-altered high- and intermediate-risk non-muscle invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Antoni Vilaseca Cabo, MD, discusses phase 1 data presented on TAR-210 for the treatment of patients with FGFR-altered high- and intermediate-risk #NMIBC. #BLCSM https://t.co/zkjP2DjWFu
-
-
Mashup Score: 0Nadofaragene Firadenovec Delivers Durable Responses in Bladder Cancer - 10 month(s) ago
Findings from a 3-year follow-up analysis found that nadofaragene firadenovec demonstrated durable, lasting results for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Data from a 3-year follow-up analysis of a phase 3 study evaluating nadofaragene firadenovec-vncg in high-risk BCG-unresponsive #NMIBC showed that the agent delivered a sustained, durable response. #BLCSM | @ferring https://t.co/aiw9e3Hdmf
-
-
Mashup Score: 1Tailoring Treatment for High-Risk Bladder Cancer: Beyond BCG - 11 month(s) ago
In an interview with Targeted Oncology, Stephen Williams, MD, discussed a retrospective cohort study analyzing intravesical gemcitabine usage vs Bacillus Calmette-Guérin for the treatment of high-risk non-muscle invasive bladder cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Here, Stephen Williams, MD, discussed a retrospective cohort study analyzing intravesical gemcitabine usage vs BCG for the treatment of high-risk non-muscle invasive bladder cancer. #NMIBC #BLCSM https://t.co/PnyNSSHKgX
-
A high CR rate at 3 months was seen among patients with low-grade, intermediate-risk #NMIBC treated with UGN-102, according to data from the phase 3 ENVISION trial. #blcsm https://t.co/hGycnCVrym https://t.co/h1nvfZ7UyO